The aim of the evidence is to help with the decision making process regarding whether Rituximab should be licensed by NICE for use in the treatment of Wegener's Granulomatosis (GPA) and Microscopic Polyangiitis
If you have not already taken part and you are receiving Rituximab for your Vasculitis there are still 4 weeks to go before John submits his report and evidence to NICE.